loader

psychedelics investing

LATEST ARTICLES
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Psychedelics Investing

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Psychedelics Investing

Right Season is Unaware of Any Material Change

Psychedelics Investing

CSE Bulletin: Delist - Better Plant Sciences Inc.

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
psychedelics investing

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Glowing mushrooms with colorful graphs in the background on a dark surface.
psychedelics investing

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
psychedelics investing

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
psychedelics investing

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
psychedelics investing

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Participate in Stifel Virtual CNS Forum
psychedelics investing

Compass Pathways to Participate in Stifel Virtual CNS Forum

Latest News

More News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES